Surmodics (SRDX)
(Delayed Data from NSDQ)
$38.42 USD
+0.22 (0.58%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $38.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$38.42 USD
+0.22 (0.58%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $38.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Zacks News
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.
Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop
by Zacks Equity Research
Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.
Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.
Walgreens-Alphabet Join Forces to Control Healthcare Costs
by Zacks Equity Research
Walgreens (WBA) and Alphabet's arm Verily to start a medication adherence pilot project that will deploy equipment and other methods to improve adherence.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
Here's Why You Should Hold HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
by Zacks Equity Research
With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.
Baxter Stock up on Launch of Disposable Curved Applicator
by Zacks Equity Research
Baxter's (BAX) wide array of surgical products see lucrative market prospects.
Surmodics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Surmodics has been struggling lately, but the selling pressure may be coming to an end soon.
GNC Holdings Global Business Strong, Same Store Sales Weak
by Zacks Equity Research
GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.
Here's Why You Should Buy Haemonetics (HAE) Stock Right Now
by Zacks Equity Research
Haemonetics (HAE) continues to witness strong growth in Plasma franchise.
Cerner's (CERN) Millennium Picked by Mid-Valley Hospital
by Zacks Equity Research
Cerner's (CERN) EHR platforms have seen a series of developments in recent times.
Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look
by Zacks Equity Research
DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.
Hologic's (HOLX) New Offering to Revitalize Cynosure Division
by Zacks Equity Research
The latest launch along with certain new developments is expected to boost top-line contribution from Hologic's (HOLX) Cynosure division in the near term.
Bruker Profits from NANO & CALID, New Buyout Holds Promise
by Zacks Equity Research
Bruker (BRKR) looks to gain from high demand for ADVANCE X-ray and nano-analysis products. The CALID Group also raises hope with high-single digit robust year-to-date revenues.
Thermo Fisher (TMO) Rides on New Buyouts and APAC Strength
by Zacks Equity Research
We are upbeat about Thermo Fisher's (TMO) recent buyout of Advanced Bioprocessing business, which will add complementary cell culture products to the company's bioproduction suit.
Varian Medical's Eclipse Picked by Paul Scherrer Institute
by Zacks Equity Research
Varian Medical's (VAR) latest developments fortify its foothold in the global cancer therapeutics market.
Here's Why You Should Hold Baxter International (BAX) Now
by Zacks Equity Research
Baxter's (BAX) recent string of developments boost the stock while segmental softness is a concern.
Edwards Lifesciences Advances in AI With Bay Labs Tie-Up
by Zacks Equity Research
Through the tie-up, Edwards Lifesciences (EW) aims at improving detection of heart diseases and enhancing quality by using Bay Labs' ability to apply AI to cardiovascular imaging.
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
by Zacks Equity Research
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
by Zacks Equity Research
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.